Repair Biotechnologies, Inc.
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Cardiovascular
US-based Repair Biotechnologies develops the first potentially curative therapy for atherosclerotic cardiovascular disease, derived from a novel platform approach to undruggable aspects of cholesterol metabolism. The company's lead messenger RNA drug has rapidly and sizably improved exercise performance, improved liver health, and regressed estabished arterial plaque in preclinical studies. These improvements continue to accrue in treated animals for months following cessation of therapy. The FDA has awarded Orphan Drug Designation for the treatment of the accelerated atherosclerosis of homozygous familial hypercholesterolemia, and the company is preparing for IND submission in 2027. The therapeutic platform is broadly applicable to a range of important and largely irreversible conditions beyond cardiovascular disease, including MASH, neurodegenerative diseases, and others.
Company HQ City:
Syracuse
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
REP-0004.
CEO
Reason
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
06/2027
What is your next catalyst (value inflection) update?
IND submission.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}